摘要
目的:探讨长疗程口服更昔洛韦预防肾移植术后巨细胞病毒(CMV)病的有效性及安全性。方法:2004年1月至2007年1月在本院进行首次肾移植的57例患者,分为预防组和对照组。预防组27例,术后即予更昔洛韦口服,每次1g,3次/d,维持用药3个月;对照组30例,不服用任何抗病毒药物。结果:长疗程预防性口服更昔洛韦能降低CMV病发病率(14.8%比20.0%),但未达到统计学差异(P>0.05);能明显推迟CMV病发病时间[(77.3±11.1)d比(63.2±14.1)d,P<0.05];降低CMV病发病时的严重程度,缩短病程[(11.5±2.2)d比(13.0±1.0)d,P<0.05];急性排斥率下降(11.1%比20.0%),但未达到统计学差异(P>0.05);预防组中2例发生不良反应。结论:长疗程口服更昔洛韦对CMV病的发病率无显著影响,但可降低CMV病的病死率,缩短病程。口服更昔洛韦的不良反应少。
Objective To assess the efficacy and safety of prolonged cytomegalovirus（CMV） prophylaxis with oral ganciclovir intake in renal transplant recipients. Methods Fifty-seven patients, who underwent renal transplantation from January 2004 to January 2007, were divided into two groups. Ganciclovir was orally administered 1 g three times per day for 3 months in the preventive group （n=27）, while the others who did not receive anti-virus treatment were served as control （n=30）. Results The incidence of CMV diseases and the rate of graft rejection were similar in both groups. The time-to-CMV-disease after transplantation in preventive group was significantly longer than that in control group （77.3± 11.1 vs 63.2±14.1, P〈0.05）. Moreover, less severe CMV disease was observed in the preventive group. The days of CMV disease remission were shorter in preventive group than those in control group （11.5±2.2 vs 13.0±1.0, P〈0.05）. No significant side-effect was observed during ganciclovir treatment. Conclusions The results of this study do not indicate that prolonged prophylaxis with oral ganciclovir intake could reduce the risk of CMV diseases after renal transplantation. Yet, this treatment could reduce the mortality of CMV diseases and shortened the duration of disease remission.
出处
《内科理论与实践》
2007年第6期420-423,共4页
Journal of Internal Medicine Concepts & Practice
关键词
更昔洛韦
肾移植
巨细胞病毒
预防
Ganciclovir
Cytomegalovirus
Renal transplantation
Prophlaxis
